Clinical Trial Update: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating retatrutide (LY3437943) for type 2 diabetes in participants with obesity or overweight has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes, Obesity | Phase 3 | Status: COMPLETED